STEVENSON, Md., April 09, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Obalon Therapeutics, Inc. (Nasdaq:OBLN) (“Obalon” or the “Company”) securities during the period between October 5, 2016 and January 23, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Obalon securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company recognized revenue in violation of Generally Accepted Accounting principles and that the Company lacked adequate internal controls over accounting and financial reporting.
According to the complaint, following Obalon’s January 23, 2018 press release disclosing that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017” and that “Obalon’s Audit Committee will oversee an internal investigation of these allegations,” the value of Obalon shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Obalon securities purchased on or after October 5, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Apple Restores Telegram to App Store After Content Policy Violation
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Capital One Says AML Review Led to Closure of Trump Organization Accounts
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
Telegram Restored on Apple App Store After Temporary Removal
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Japan Earthquake Disrupts Auto and Chip Supply Chains
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 



